Evidence map›Paper›PMID 41944958›Full record

ArticleInternational journal of hematology2026

Ten-color multicolor flow cytometry-based measurable residual disease at pre-transplantation predicts relapse of acute myeloid leukemia: a prospective study.

Kumiyo Tazoe, Hirohisa Nakamae, Yosuke Makuuchi, Masatomo Kuno, Teruhito Takakuwa, Hiroshi Okamura, Asao Hirose, Mika Nakamae, Mitsutaka Nishimoto, Yasuhiro Nakashima and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kumiyo TazoeDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan.
Hirohisa NakamaeDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan. hirohisa@omu.ac.jp.ORCID http://orcid.org/0000-0003-4203-990X
Yosuke MakuuchiDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan.
Masatomo KunoDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan.
Teruhito TakakuwaDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan.
Hiroshi OkamuraDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan.
Asao HiroseDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan.
Mika NakamaeDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan.
Mitsutaka NishimotoDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan.
Yasuhiro NakashimaDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan.
Hideo MiyagawaPreventive Medicine and Environmental Health, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Masayuki HinoDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka, 545-8585, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveMeasurable residual disease (MRD) is a key prognostic factor for outcomes following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia. To enhance predictive performance, we developed a combined MRD assessment method that integrates the proportion of residual leukemic cells of ten-color multicolor flow cytometry (MFC) with peripheral blood WT1 mRNA expression.

methodsForty-six patients with acute myeloid leukemia who underwent allo-HSCT at our institution between October 2013 and December 2019 were enrolled. We prospectively analyzed the prognostic impact of ten-color MFC, peripheral blood WT1 mRNA, and combined MRD assessment before transplantation.

resultsBoth ten-color MFC-based MRD and peripheral blood WT1 mRNA levels above predefined thresholds were significantly associated with an increased risk of relapse after allo-HSCT. However, the results of the multivariate and ROC analyses suggest that ten-color MFC may be a stronger predictor than WT1 mRNA. Moreover, adding peripheral blood WT1 mRNA to ten-color MFC-based MRD reduced the predictive accuracy compared with MFC alone.

Indexed as

Flow CytometryHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteNeoplasm, ResidualAdultFemaleHumansMaleMiddle AgedPrognosisProspective StudiesRecurrenceRNA, MessengerTransplantation, HomologousWT1 ProteinsYoung AdultRNA, MessengerWT1 protein, humanWT1 ProteinsAcute myeloid leukemiaAllogeneic stem cell transplantationFlow cytometryMeasurable residual disease

Identifiers

PMID41944958

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.